173 related articles for article (PubMed ID: 21168197)
1. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.
Growdon WB; Roussel BN; Scialabba VL; Foster R; Dias-Santagata D; Iafrate AJ; Ellisen LW; Tambouret RH; Rueda BR; Borger DR
Gynecol Oncol; 2011 Apr; 121(1):212-7. PubMed ID: 21168197
[TBL] [Abstract][Full Text] [Related]
2. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
3. Oncogene alterations in endometrial carcinosarcomas.
Biscuola M; Van de Vijver K; Castilla MÁ; Romero-Pérez L; López-García MÁ; Díaz-Martín J; Matias-Guiu X; Oliva E; Palacios Calvo J
Hum Pathol; 2013 May; 44(5):852-9. PubMed ID: 23199529
[TBL] [Abstract][Full Text] [Related]
4. Mutational and Immunophenotypic Profiling of a Series of 8 Tubo-ovarian Carcinosarcomas Revealed a Monoclonal Origin of the Disease.
Trento M; Munari G; Carraro V; Lanza C; Salmaso R; Pizzi S; Santoro L; Chiarelli S; Dal Santo L; Nardelli GB; Saccardi C; Nicoletto O; Baldoni A; Rugge M; Fassan M
Int J Gynecol Pathol; 2020 Jul; 39(4):305-312. PubMed ID: 31688243
[TBL] [Abstract][Full Text] [Related]
5. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
[TBL] [Abstract][Full Text] [Related]
6. Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
Lu W; Wei H; Li M; Wang H; Liu L; Zhang Q; Liu L; Lu S
Mol Med Rep; 2015 Jul; 12(1):1219-24. PubMed ID: 25815786
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA, HRAS and KRAS gene mutations in human penile cancer.
Andersson P; Kolaric A; Windahl T; Kirrander P; Söderkvist P; Karlsson MG
J Urol; 2008 May; 179(5):2030-4. PubMed ID: 18355852
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic carcinosarcoma with the same KRAS gene mutation in both carcinomatous and sarcomatous components: molecular evidence for monoclonal origin of the tumour.
Bai Q; Zhang X; Zhu X; Wang L; Huang D; Cai X; Zhou X; Wang J; Sheng W
Histopathology; 2016 Sep; 69(3):393-405. PubMed ID: 27307095
[TBL] [Abstract][Full Text] [Related]
10. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Zhao S; Bellone S; Lopez S; Thakral D; Schwab C; English DP; Black J; Cocco E; Choi J; Zammataro L; Predolini F; Bonazzoli E; Bi M; Buza N; Hui P; Wong S; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Facchetti F; Falchetti M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Mane S; Angioli R; Terranova C; Quick CM; Edraki B; Bilgüvar K; Lee M; Choi M; Stiegler AL; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12238-12243. PubMed ID: 27791010
[TBL] [Abstract][Full Text] [Related]
11. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas.
Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shiratori K; Kawamura S; Kobayashi M; Shimizu M; Ban S; Koyama I; Higashi M; Shin N; Ishida K; Morikawa T; Motoi F; Unno M; Kanno A; Satoh K; Shimosegawa T; Orikasa H; Watanabe T; Nishimura K; Harada Y; Furukawa T
Am J Surg Pathol; 2011 Dec; 35(12):1812-7. PubMed ID: 21945955
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Tie J; Lipton L; Desai J; Gibbs P; Jorissen RN; Christie M; Drummond KJ; Thomson BN; Usatoff V; Evans PM; Pick AW; Knight S; Carne PW; Berry R; Polglase A; McMurrick P; Zhao Q; Busam D; Strausberg RL; Domingo E; Tomlinson IP; Midgley R; Kerr D; Sieber OM
Clin Cancer Res; 2011 Mar; 17(5):1122-30. PubMed ID: 21239505
[TBL] [Abstract][Full Text] [Related]
14. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy.
Italiano A; Cortot AB; Ilie M; Martel-Planche G; Fabas T; Pop D; Mouroux J; Hofman V; Hofman P; Pedeutour F
Int J Cancer; 2009 Nov; 125(10):2479-82. PubMed ID: 19681124
[TBL] [Abstract][Full Text] [Related]
15. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
[TBL] [Abstract][Full Text] [Related]
16. Mutations in PIK3CA are infrequent in neuroblastoma.
Dam V; Morgan BT; Mazanek P; Hogarty MD
BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308
[TBL] [Abstract][Full Text] [Related]
17. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.
Byron SA; Gartside M; Powell MA; Wellens CL; Gao F; Mutch DG; Goodfellow PJ; Pollock PM
PLoS One; 2012; 7(2):e30801. PubMed ID: 22383975
[TBL] [Abstract][Full Text] [Related]
18. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
Ghosh A; Lai C; McDonald S; Suraweera N; Sengupta N; Propper D; Dorudi S; Silver A
Exp Mol Pathol; 2013 Feb; 94(1):103-8. PubMed ID: 22982087
[TBL] [Abstract][Full Text] [Related]
19. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
Kogita A; Yoshioka Y; Sakai K; Togashi Y; Sogabe S; Nakai T; Okuno K; Nishio K
Biochem Biophys Res Commun; 2015 Feb; 458(1):52-6. PubMed ID: 25623536
[TBL] [Abstract][Full Text] [Related]
20. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
